Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women aged from 18 to 70 years;~2. Histologically proven invasive unilateral breast cancer (regardless of the type);~3. Initial clinical condition compatible with complete initial resection;~4. No residual macro or microscopic tumor after surgical excision;~5. Beginning of chemotherapeutic treatment no later than day 42 after the initial surgery;~6. positive lymph node or negative lymph node with tumor size \> 1.0cm~7. Patient presenting one of the following criteria (reviewed before randomization by referent pathologist):~   Triple negative （ER-PR-Her-2-） Hormone receptor negativity is defined as ER\<1%, PR\<1% (IHC), HER2 negativity is defined as IHC 0-1+, or \[IHC 2+ and FISH or CISH negative\].~8. No clinically or radiologically detectable metastases (M0);~9. No peripheral neuropathy \> 1;~10. WHO Performance status (ECOG) of 0 or 1;~11. Adequate recovery from recent surgery (at least one week must have elapsed from the time of a minor surgery (excluding breast biopsy); at least three weeks for major surgery);~12. Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x 109/l, Hemoglobin \> 9 g/dl);~13. Adequate hepatic function: ASAT and ALAT ≤ 3 ULN alkaline phosphatases ≤ 2.5 ULN,total bilirubin ≤ 1,5 ULN;~14. Adequate renal function: serum creatinine ≤ 1 ULN;~15. Patients accepting contraception intake during the overall length of treatment if of childbearing potential;~16. Adequate cardiac function, LEVF value \> 50% by Muga scan or echocardiography;~17. Signed written informed consent.~Exclusion Criteria:~1. Bilateral breast cancer or patient with controlateral DCIS;~2. Any metastatic impairment, including homolateral sub-clavicular node involvement,regardless of its type;~3. Any T4 lesion (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer);~4. ER+ or PR+ or Her-2 overexpression~5. Any clinically or radiologically suspect and non-explored damage to the controlateral breast;~6. Any chemotherapy, hormonal therapy or radiotherapy before surgery;~7. Previous cancer (excepted cutaneous baso-cellular epithelioma or uterin peripheral ephitelioma) in the preceding 5 years, including invasive controlateral breast cancer;~8. Patients already included in another therapeutic trial involving an experimental drug;~9. Patients with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study;~10. LEVF \< 50% (MUGA scan or echocardiography);~11. Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension (\>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to randomization;~12. Known prior severe hypersensitivity reactions to agents containing Cremophor EL;~13. Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and up to 8 weeks after treatment completion;~14. Women who are pregnant or breastfeeding. Adequate birth control measures should be taken during study treatment phase;~15. Women with a positive pregnancy test en enrollment or prior to study drug administration;~16. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;~17. Individual deprived of liberty or placed under the authority of a tutor.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 6 cycles of PC adjuvant chemotherapy (Type: EXPERIMENTAL): paclitaxel 80 mg/m2 and carboplatin (area under the curve \[AUC\]= 2) on day 1, 8, 15 every 28 days for six cycles
- 3 cycles of FEC followed by 3 cycles of Docetaxel (Type: ACTIVE_COMPARATOR): fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).